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THE VIRTUE OF MODERATION
The quest for balance and moderation is well en -trenched in major belief systems, ancient traditions
and philosophical musings. For example, Aristotle
(384–322 BC) noted that “the virtue of justice consists in
moderation’’ while Muslims are reminded in the Quran,
“and thus We willed you to be a community of the
middle way’’. The Buddha (563–483 BC) also under -
stood this when overhearing a lute player and realizing
that the harmonious sounds produced depended on the
lute strings’ not being tuned too tightly or too loosely.
Likewise, the well-being of individual cells and organisms
depends on a constant internal environment, referred
to as ‘homeostasis’’. The term ‘homeostasis’ derives
from the Greek homoios (‘same’) and stasis (‘condition’)
and was coined in 1929 by the American physiologist
Walter Cannon.1,2 However, the concept was earlier
recognized by others. The French scientist Claude
Bernard (1813–1878) used the term milieu interieur and
noted that “all the vital mechanisms, varied as they are,
have only one object, that of preserving constant the
conditions of life in the internal environment’’.1,2 More -
over, some suggest that the celebrated physician Ibn
Sina (Avicenna) (980–1037) was aware of intrinsic and
extrinsic factors and their role in the development of
disease, and also of the body’s interior milieu and
homeostasis.3,4
External environmental exposures depend largely on
lifestyle choices (e.g. nutrition and physical activity) and
the outside environment (e.g. urbanization and pollu -
tion). Organisms employ numerous mechanisms to
ensure that their internal milieu is exquisitely balanced,
for example through continuous monitoring of internal
and external environments. If required, the body elicits
the necessary adjustments to remain near its ‘set point’.
Here the organism functions inside particular limits
within specific environments/contexts. If these set limits
are exceeded or not adequately met, it is sensed and
organisms initiate the necessary adjustments to again
operate within their set confines.2 However, organisms
are sometimes unable to maintain homeostasis, leading
to cellular dysfunction and the onset of diseases. This
may occur either due to deficiency (needs of cells not
met) or toxicity (cells poisoned by oversupply).2 As a
result of such disruption, organisms trigger various
pathways within affected cells to limit damage caused.
However, in the longer term, this disruption may also
result in maladaptation and disease onset.  
The human body consists of various systems (e.g.
nervous, digestive, endocrine and cardiovascular) that
function in concert to ensure overall well-being. Since
no system operates as an independent unit, disruption
of one or more systems may result in serious conse -
quences for other systems of the body and threaten
overall well-being.2 For example, if homeostasis of the
cardiovascular system is compromised due to internal
and/or external exposures, it will result in serious
consequences for the host organism.
IMPACT OF CONTEMPORARY
EXTERNAL EXPOSURES 
AWorld Health Organization report warns of theescalating global burden of cardiovascular diseases
(CVD),5 and a recent study investigating the worldwide
prevalence of CVD projects a marked increase for its
incidence in developing nations (including South Africa)
by 2020.6 Data suggest that the dramatic surge in CVD
rates in developing countries is due to accelerated
urbanization and associated lifestyle changes (e.g. poor
nutritional choices, obesity and decreased physical acti -
vity).7 For example, urbanization is a growing problem
in Africa, drastically altering lifestyle and thereby leading
to changes in body composition and shape, which
ultimately increases the risk for insulin resistance, 
type 2 diabetes and CVD.8 Demographic change in
South Africa is also a major contributing factor; for
example, the number of individuals aged 35–64 years
old is projected to rise three-fold by 2025 despite the
threat of HIV/AIDS.9 Moreover, antiretroviral treat -
ment (protease inhibitors) is associated with increased
onset of insulin resistance, dyslipidemia and lipodys -
trophy.9 Patients on chronic antiretroviral treatment
will further swell the growing burden of cardio-meta -
bolic diseases in developing countries such as South
Africa. This sentiment is aptly echoed by Alafia Samuels
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6(University of the West Indies, Barbados) who state
that “we have to be patient-focused. We cannot cure (a
patient’s) HIV and then send them off to die with
diabetes.’’10 Projections show that the global incidence
of type 2 diabetes will continue to rise, with the African
continent facing ~50% increase in numbers.11 Since
cardiovascular complications are common in patients
with type 2 diabetes, this will further increase the over -
all burden of disease.12 The higher mortalities and
morbidities associated with increased type 2 diabetes
and CVD rates will have serious socio-economic im -
plications, including disruption of family units, greater
health care costs and diminished productivity. This will
eventually threaten the sustainable development of
South Africa and the rest of the African continent. 
THE METABOLIC SYNDROME
An emerging paradigm suggests that a cluster ofmetabolic abnormalities, referred to as the meta -
bolic syndrome, is associated with increased risk for the
development of both type 2 diabetes and CVD.13,14
Here an underlying rationale is to provide a clinically
accessible diagnostic tool that will allow for the early
identification of individuals at risk for the development
of type 2 diabetes and/or CVD. In broad terms, the
meta bolic syndrome is characterized by a ‘deadly quar -
tet’, including impaired glucose regulation (hyper -
glycemia), poor lipid profile (dyslipidemia), hypertension
and obesity.13,14 Since abdominal fat deposition is
associated with more serious health implications than
fat accumulating elsewhere,7 the International Diabetes
Federation now includes increased waist circumference
as a prerequisite for the diagnosis of the metabolic
syndrome.13,14 Of note, central obesity is thought to be
the single most important factor contributing to the
development of the metabolic syndrome. Moreover,
adi pose tissue is now recognized to be an active meta -
bolic organ, secreting hormones and cytokines that may
have both paracrine and endocrine effects on different
tissue types.
In our opinion, the alarming projections for the onset
of type 2 diabetes and CVD necessitate a compre hen -
sive strategy to deal with this problem and therefore
our laboratory is coordinating a multi-pronged project
to evaluate the metabolic syndrome within the southern
African context. Here our focus is to 1) investigate the
onset of metabolic risk factors in southern African
communities, 2) gain insight into the basic mechanisms
whereby metabolic risk factors actually trigger type 2
diabetes and CVD onset, 3) establish unique therapeutic
interventions to blunt the onset of insulin resis -
tance/type 2 diabetes and CVD and 4) develop novel
methods to detect the onset of diabetes and CVD.
The rest of this document will concentrate on
selected research work conducted in our laboratory
over the last years, emphasizing perturbed metabolism
and its contribution to the onset of cardio-metabolic
diseases. Our work focused particularly on unraveling
the mechanisms underlying heart metabolism and
function within the setting of type 2 diabetes and cardiac
hypertrophy (thickened cardiac muscle). Here our
rationale is that such an understanding will allow for the
development of novel diagnostic tools and therapies to
treat the growing burden of cardio-metabolic diseases
in developed and developing nations.
ONSET OF METABOLIC SYNDROME
IN SOUTH AFRICAN POPULATIONS
Of concern is that relatively limited data are availa -ble for the prevalence of the metabolic syndrome
in South Africa and the African continent, thus limiting
the development of effective strategies to deal with the
increasing burden of disease for type 2 diabetes and
CVD. In light of this, we began investigating the inci -
dence of metabolic risk factors in a younger student
popu lation (< 30 years old) at Stellenbosch Uni versity.
Here risk factors (4% of student population) presented
at a much younger age than commonly ex pected.15 Our
data showed some gender-based diffe rences, with
women displaying a greater prevalence of in creased
waist circumference while men exhibited higher blood
pressures. Waist circumference in the female study
population was positively associated with blood pres -
sures and cholesterol levels. We propose that these
differences are related to student behavioural patterns,
in other words, male students displaying poor lifestyle
choices (e.g. increased consumption of ‘junk food’) and
female students exercising less than would normally be
expected. We therefore recommend that it is impera -
tive to screen young students in order to iden tify meta -
bolic risk profiles relatively early on and to thereafter
initiate appropriate lifestyle changes.
We are presently expanding our initial work in Stel -
len bosch to include a greater number of students and
also the more senior campus population (> 30 years
old). Our data show a marked incidence of metabolic
risk factors in the older Stellenbosch campus population
(38–58 years old) (see Table 1), with elderly men the
most vulnerable group (unpublished data). Since obesity
and poor lifestyle choices (older men) appear to be key
7mediators of metabolic risk factor onset in this group,
we advise improved body weight management (e.g. in -
creased exercise) and sound lifestyle choices (e.g. lower
alcohol intake). Together, these data show that meta -
bolic risk factors present a) at a much earlier age than
what would be commonly expected and b) at alar ming
rates in the older population. This therefore neces si -
tates effective strategies to counter the pre dicted onset
of type 2 diabetes and CVD. Moreover, it also requires
further investigation and identification of mechanisms
whereby risk factors eventually cause the development
of cardio-metabolic diseases.
THE REDUCTIONIST APPROACH
AND BASIC SCIENCE
To better understand the underlying molecularmecha nisms driving the onset of disease states, bio -
medical scientists currently adopt ‘reductionism’ as
their operating paradigm. The basic rationale of re -
ductionism is that a complex system, for example the
onset of a particular disease state within a human being,
can be understood by examining its basic elements. The
approach is to reduce a specific disease condition to its
basic cellular and molecular elements (e.g. genes, pro -
teins and enzymes). Moreover, biomedical scientists
employ various experimental systems (e.g. animal and
cell-based models) in their laboratories to investigate
and identify molecular events that may ultimately result
in the onset of a particular disease.
Although this particular worldview has resulted in
significant strides being made to develop novel thera -
pies, its shortfalls are also increasingly being high lighted.
For example, scientists are now facing ‘infor mation
over load’ with the overspecialization of disci plines often
resulting in a plethora of molecular pathways with sig -
nifi cant cross-talk a compounding factor. This may im -
pair information flow and/or meaningful and coherent
synthesis/understanding of the various molecular path -
ways and regulators continuously being identified.
Over simplification is another potential problem since
thera peutic advances tested within the laboratory setting
are not always effective when employed in the clinic. In
agreement, Dr Claude Lenfant, former director of the
National Heart, Lung, and Blood Institute (NHLBI),
states, “Enormous amounts of new knowledge are
barrelling down the information highway, but they are
not arriving at the doorsteps of our patients.’’16 As a
result, major institutions such as the National Insti tutes
of Health in the United States of America have adjusted
their strategic approach with a renewed inte rest in the
more rapid ‘translation’ of laboratory-based science in -
to the clinic and to also foster greater co-ope ration be -
tween basic scientists and clinicians. Further more, recent
approaches such as ‘systems bio logy’ are also attemp -
ting to deal with the short comings of mole cular reduc -
tionism. However, Joyner17 correctly points out that
systems biology still employs a cell-centric focus with
limited understanding and appli cation beyond the cell.
Since some of these approaches are still rooted in
the existing scientific worldview, it is likely that the
current paradigm will need to be revised in future to
reflect a more integrative approach. Physiology as a
 Female 
students 
(< 30 
years) 
Female 
Staff 
(> 30 
years) 
P-values
Systolic BP 
(mmHg) 
 
119 132.96  
 
 
 
P < 0.001 
Diastolic BP 
(mmHg) 
 
77.65 88.61 
Glucose (mmol/L) 
 
4.6 7.1 
Triglycerides 
(mmol/L) 
 
1.47 2.78 
Total Cholesterol 
(mmol/L) 
 
4.65 5.19 p < 0.05 
BMI (kg/m2) 
 
20.98 27.99 P < 0.001 
Table 1: Metabolic risk factors for female students
and staff members at Stellenbosch University
Older Stellenbosch University female staff exhibits a
marked increase in metabolic risk factors and anthro -
pometric measures compared to the younger population.
Here we found higher blood pressures and fasting levels
of several metabolites, namely increased glucose,
triglycerides and total cholesterol. Note: systolic blood
pressures ≥ 130 and/or diastolic pressures ≥ 85, fasting
triglyceride ≥ 1.7 mmol/L and fasting glucose levels ≥ 5.6
mmol/L make up some of the criteria that constitute the
metabolic syn drome, according to the International
Diabetes Federation’s definition. We are currently in the
process of evaluating low-density lipoprotein and high-
density lipoprotein levels in these populations. The body
mass index (BMI) – marker of obesity – of older women
was also higher than the cut-off value of 25 kg/m2 and
falls within the range that is regarded as pre-obese 
(n = 117).
discipline may indeed be able to help bridge the gap
between molecular reductionism and complexity. Here
the idea is put forward that physiology may fill the
current intellectual void since its focus is to understand
the integrated functions of organs/organisms within the
larger context of homeostasis and regulation.17,18
THE ABCS OF HEART METABOLISM
The main focus of our research work over the lastyears was on the role of altered metabolism of the
heart and its impact on myocardial energy (adenosine
triphosphate [ATP]) production and contractile func -
tion. The normal human heart requires between 3.5 and
5 kg of ATP per day to sustain its function.19 An ade -
quate supply of oxygen and fuel substrates allows for
their metabolism to generate enough ATP to keep the
heart pumping. Fatty acids serve as the major fuel sub -
strate for the normal, fasting adult mammalian heart,
providing the majority of its energetic requirements.19
The rest of the heart’s ATP is derived from glucose and
lactate in nearly equal proportions, while ketone bodies
are also utilized as a fuel substrate under certain con di -
tions. After uptake by specific cardiac fatty acid trans -
porters, long-chain fatty acids are esterified by fatty
acyl-CoA synthetase and may either be stored as trig -
lycerides or transported into the mitochondrion for
fatty acid β-oxida tion. 
Mitochondrial fatty acid uptake is controlled by
malo nyl-CoA, a potent allosteric inhibitor of carnitine
palmi toyltransferse-1 (CPT-1), the rate-limiting enzyme
regulating this process.20 The rates of synthesis and de -
gradation of malonyl-CoA in the heart are stringently
con trolled by acetyl-CoA carboxylase (ACC) and malo -
nyl-CoA decarboxylase (MCD), respectively. Two ACC
isoforms with distinct functional roles have been identi -
fied in mammals, namely ACCa and ACCβ.21,22 ACCa
is enriched in lipogenic tissues where it plays a key role
in fatty acid biosynthesis. Conversely, ACCβ is  abun -
dantly expressed in oxida tive tis sues  (e.g . hea rt and
skeleta l muscle) and is  phys ica lly a s so cia ted with
mitochondria .23 ACCβ is  therefore s trong ly impli -
cated in the control of mitochondria l fa tty acid β-oxi -
dation. In support, we found de creased myo ca r dia l
ma lonyl-CoA levels  and in crea sed ca rdia c mito -
chondrial fa tty a cid β-oxida tion in ACCβ mutant mice
(displa ying  reduced ACCβ activity).24
We also performed studies on transcriptional
mecha nisms that regulate ACCβ gene express ion to
iden tify novel ‘on’ and ‘off’ switches  tha t regula te
this  process . This  approach was  adopted s ince
both decrea sed and increa sed fa tty a cid β-oxidation
rates are implicated in the onset of insulin resistance
and dia betes-related CVD. We hypothesized that this
apparent contradiction may be clarified when viewing
such fin dings within particular contexts, for example ex -
peri mental models employed and also the stage of
disease progression. Thus the identification of both acti -
vators and inhibitors of ACCβ gene expression offers
thera peutic promise depending on the particular con -
text. Here we identified a unique transcriptional acti -
vator, upstream stimulatory factor 1 (USF1), that in -
creases car diac ACCβ gene express ion.25 Further -
more, we also identified nuclear respiratory factor-1
(NRF-1) as a novel inhibitor of ACCβ gene ex pres -
sion.26 We therefore propose that both USF1 and NRF-
1 are useful targets to control malonyl-CoA levels and
thereby up- or downregulate cardiac mito chondrial
fatty acid β-oxida tion, depending  on the pa rticula r
intra  cellula r milieu (see F igure 1). 
Upstream, 5΄-AMP -a ctiva ted protein kina s e
(AMP K) is  a  pivota l fuel sensor tha t is  a ctiva ted in
response to environmenta l s tress  (e.g . oxygen la ck
and nu trient depri va tion) with the primary a im to
res tore both cellu la r and whole body energy ba -
lance.27 AMPK activates both myocardial glucose and
fatty acid metabolic pathways to ultimately ensure in -
creased pro duction of myocardial ATP when re quired.
It is well established that AMPK can phospho rylate and
inhibit ACCβ acti vity, thereby lowering  ma lonyl-CoA
levels  and s timula ting  mitochondria l fa tty a cid β-
oxida tion. We a lso found, for the firs t time a s  fa r a s
we a re aware, tha t AMP K dose-de pen dently re du -
ces ACCβ gene promoter a ctivity26 (see Figure 1).
AMPK is therefore able to inhibit ACCβ a t both
transcrip tiona l and enzyme a ctivity levels . After its
mito chon dria l up take, the fa tty a cyl-CoA enters  the
β-oxida  tion spira l tha t success ively shor tens  fa tty
a cids  by two car bons (per cycle) and gene ra tes
NADH and FADH2. The reducing equi valents gene rated
subse quent ly donate electrons to the mito chondrial
electron transport chain for ATP production. Mito -
chondrial fatty acid β-oxida  tion pro vides ~60–90% of
the tota l ener g y require ments  of the hea rt.19
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trans porter (GLUT) isoforms, namely GLUT1 and GLUT4.
GLUT1 is enriched during the fetal stages of develop -
ment, while GLUT4 is postnatally induced, in sulin-
depen dent and the major transporter in the adult
heart.19 After insulin binds to the membrane-bound in -
sulin receptor, it triggers signaling cascades (e.g. PI3
kinase, Akt and AS160) that allow GLUT4 to migrate
from intracellular vesicular stores to the sarcolemma,
thereby increasing myocardial glucose uptake1,19 (see
Figure 1). Glucose subsequently enters the glycolytic
pathway and is ultimately converted to pyruvate with
the production of two ATP molecules (per glucose
mole cule) without any oxygen require ments (anaero bic
glycolysis). Additional metabolic fates of glucose include
its conversion to glycogen (for rapid utilization at a later
stage) and flux through the polyol, hexosamine bio -
synthetic and pentose phosphate pathways. Pyruvate
subsequently enters the mitochon drion where it is
further catabolized via the Krebs cycle to generate re -
ducing equivalents (NADH and FADH2) that can
eventually enter the electron transport chain to 
pro duce mitochondrial ATP. The complete breakdown
of glucose (glycolysis and glucose oxidation) accounts
for ~10–40% of the heart’s energy requirements.19
NADH and FADH2 generated by glucose and fatty acid
metabolism can initiate electron transfer through the
mitochondrial electron transport chain. Electrons are
passed through complex I (NADH dehydrogenase) and
complex II (succinate dehydrogenase) to coenzyme Q.
Figure 1: Basic scheme of cardiac fatty acid and glucose metabolism 
Fatty acids are taken up by specific transporters (e.g. FAT – fatty acid transporter) and activated by the addition of
coenzyme A. Mito chondrial uptake is controlled by carnitine palmitoyl transferase-1 (CPT-1). Fatty acid β-oxida tion sub -
sequently occurs  within the mitochondria l ma trix to produce reducing  equiva lents  tha t can enter the electron
transport cha in (E TC) to genera te ATP  for work. Mitochon dria l fa tty a cid uptake is  regula ted by ma lonyl-CoA, a
potent inhibitor tha t is  synthes ized by a cetyl-CoA ca rboxyla se-beta  (ACCβ). We found that upstream stimulatory
factor 1 (USF1) and nuclear respiratory factor-1 (NRF-1) can increase or decrease ACCβ gene express ion, respectively,
and thus  control ca rdia c ma lonyl-CoA levels . This , in turn, will regula te CP T-1 a ctivity and ca rdia c mitochon dria l
fa tty a cid uptake. We a lso found tha t AMP K activa tion can decrea se ACCβ gene express ion. Circula ting  insulin
regula tes  g lucose uptake by promoting  GLUT4 s tora ge ves icles  to mig ra te to the cell membrane where in -
creased GLUT4 a va ila bility can now media te g lucose uptake. After its  uptake, g lucose is  ca tabolized (in severa l
s teps ) into pyruva te tha t can be taken up by mitochondria  to be further metabolized. Reducing  equiva lents
produced by the Krebs  cycle can genera te ATP  via  the E TC. 
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Reduced CoQ then transfers electrons to complex III
(ubiquinol cytochrome c reductase) that donates it to
oxidized cytochrome c. Thereafter reduced cyto chrome
c passes electrons to complex IV (cytochrome c oxi -
dase) that reduces molecular oxygen to water in the
final step. During such electron transfer (between
complex I and complex IV), a proton gradient is esta -
blished across the inner mitochondrial membrane and
exploited for ATP production. As protons move back
into the mitochondrial matrix via complex V (ATP syn -
thase) mitochondrial ATP is produced. 
Cardiac fuel substrate utilization is dynamic and may
be altered according to the prevailing physiologic or
patho physiologic milieu. For example, after meal intake
(fed state), circulating insulin levels rise to promote
myocardial glucose uptake. During the fasted state
(seve ral hours after a meal), fatty acid utilization predo -
minates with a concomitant decrease in carbohydrate
utilization and circulating insulin levels. Furthermore,
high-altitude natives, such as the Himalayan Sherpas and
the Andean Quechuas, display enhanced myocardial
glucose uptake.28 Here increased glucose utilization at
high altitude (relatively hypoxic environment) may occur
since it is a more oxygen-efficient fuel substrate to
gene rate ATP compared to fatty acids. In certain in -
stances, myocardial fuel substrate switches may also
result in maladaptive effects, thereby leading to im -
paired cardiac contractility. The latter has been the
focus of our laboratory during the last years, namely to
delineate the effects of altered metabolism in hyper -
trophied and diabetic hearts. We employed several ani -
mal and cell-based experimental systems to investigate
our hypo thesis that chronically high fuel substrate (fatty
acids and glucose) and lower oxygen levels trigger mal -
adaptive pathways, leading to decreased mitochon drial
ATP gene ration and increased cell death. This, in turn,
would be expected to lead to impaired cardiac con -
tractile function.
THE PHYSIOLOGIC
HYPERTROPHIED HEART
To gain insight into the link between physiologic andpathophysiologic cardiac hypertrophy, we estab lished
and characterized a rat model of hypobaric hypoxia-
induced right ventricular hypertrophy (physiologic).29–32
Relatively few studies have separately examined the
metabolism and function of the right and left ventricles
in response to hypertrophy. This model also allowed us
to separately examine the effects of hypoxia per se on
the heart, namely by focusing on the non hypertrophied
left ventricle.33–40 However, these findings will not be
discussed in this particular document. Rats were typi -
cally exposed to hypobaric hypoxia (11% oxygen) for
various lengths of time (1–12 weeks), and we found a
robust hypertrophic response (increased right ventri -
cular weight and myocyte size) as early as one week. No
fibrosis was detected in the hypertrophied right
ventricle (see Figure 2). 
We found coordinate induction of several genes
regu lating mitochondrial function, and increased citrate
synthase activity and mitochondrial DNA levels in the
hypertrophied right ventricle (at the two-week and
four-week time points).31,32 In parallel, mitochondrial
respiratory capacity and right ventricular contractile
function were both sustained (see Figure 3). Thus the
physiologic hypertrophied right ventricle maintains its
output by increasing mitochondrial respiratory capacity
and ATP production. We propose that patho physio -
logic hypertrophy may occur when mitochondrial 
res pira tory capacity diminishes, thereby leading to de -
creased cardiac output and eventually heart failure. In
agreement, Neubauer41 proposed that during end-stage
heart failure, the heart runs out of fuel since both glu -
cose and fatty acid oxidation are downregulated. These
data therefore indicate that the restoration of mito -
chondrial respiratory capacity in failing hearts may be a
useful therapeutic strategy to pursue. However, the
pitfalls of reductionism should be borne in mind and
such treatments be tailored to be employed within spe -
cific contexts, for example end-stage heart failure in this
instance.
THE DIABETIC HEART
We investigated cardiac contractile function andmito chondrial respiratory capacity in a rat
model of diet-induced prediabetes, in other words,
“metabolic syndrome-like’’.42 Here intake of a sub -
optimal diet in duced obesity together with insulin
resistance, in creased visceral fat, dyslipidemia and higher
plasma insulin levels. Moreover, prediabetic rats ex -
hibited reduced cardiac contractile function at baseline
toget her with decreased mitochondrial bioenergetic
capacity. We also found increased myocardial damage
when isolated rat hearts were challenged with an
ischemic insult (representing a simulated heart attack).
In agree ment, isolated heart mitochondria from pre dia -
betic rats displayed decreased mitochondrial respiration
in response to acute oxygen deprivation. In a separate
study, we also found attenuated mitochondrial respira -
tory capacity in a mouse model of type 1 diabetes.43
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Figure 3: Improved heart function
and mitochondrial respiratory
capacity in the hypertrophied right
ventricle 
After 14 days, hearts were isolated and 
ex vivo Langendorff perfusions performed
to assess contractile function. Here the
hypertrophied RV displayed increased
function – refer a). In separate experi -
ments, mitochondria were isolated and
purified to evaluate respiratory capacity.
These data show decreased mitochondrial
proton leak and increased ADP phos -
phorylation – refer b). Thus these
mitochondria become more efficient in
terms of mitochondrial ATP production.
*p < 0.05 and **p < 0.01 vs. matched
controls, respectively.
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Figure 2: Robust hypertrophic response in right ventricles exposed to hypobaric hypoxia
Male Wistar rats were exposed to 14 days of hypobaric hypoxia (45 kPa, 11% O2), and the degree of right ventricular
(RV) cardiac hypertrophy was assessed versus normoxic controls. Histologic analysis of RV heart cells revealed markedly
increased cell size – refer a) (magnification 40 x). Moreover, gene expression levels of atrial natriuretic peptide (ANP), 
a well-known marker for cardiac hypertrophy, increased significantly after 14 days – refer b). Sirius Red staining of heart
tissues detected no fibrosis in the hypertrophied RV. *p < 0.05 vs. matched controls.
These data therefore demonstrate that attenuated
mitochondrial respiratory function and bioenergetic
capacity contribute to the onset of decreased cardiac
contractile function at baseline and in response to an
ischemic insult in the prediabetic state. 
Proteomic studies
To gain further insight into the mechanisms responsible
for impaired mitochondrial function and contractile
dysfunction, we examined alterations in the mito chon -
drial proteome with the onset of type 2 diabetes. We
employed the db/db transgenic mouse model that is
charac terized by deficient leptin receptor activity, which
subsequently leads to obesity and the onset of type 2
diabetes. The db/db mice display hyper phagia (overeating)
since the fat-specific hormone leptin is now unable to
perform its usual function, in other words, acting on lep -
tin receptors in the hypothalamus to suppress appetite. 
We employed 2D-polyacrylamide gel electro phoresis
(PAGE) studies and found several differences between
control and obese hearts that broadly fall into two
categories, namely related to energy metabolism and
related to contraction/cytoskeleton, respectively.44
Here we found a significant decrease in peptide levels of
ubiquinol cytochrome-c reductase core protein 1, a
sub unit of complex III of the electron transfer chain that
catalyzes transfer of electrons from coenzyme Q to
cytochrome c. Despite attempts by the obese heart to
augment mitochondrial ATP production, attenuated
ubiquinol cytochrome-c reductase core protein 1 pep -
tide levels likely contribute to impaired mito chondrial
ATP production. We also found co-ordinated down -
regulation of key contractile/cytoskeletal proteins in the
obese heart, namely α-smooth muscle a ctin, α-ca r -
diac a ctin, myos in heavy cha in (MHC)-α and MyBP-
C. These peptides  pla y a  crucia l role to ensure sus -
tained myoca rdia l contra ctile function and cyto -
skeletal sup port. These da ta  a re cons is tent with
previous  work tha t found an MHC isoform switch
during  the onset of dia  betes , namely decrea sed
MHCα and increa sed MHCβ express ion.45 MyBP-C
is a thick filament-associated protein and provides an
additional regulatory step to myo cardial contraction.
MyBP-C gene mutations can cause hypertrophic
cardiomyopathy46 while its absence (cMyBP-C null
mice) significantly attenuates in vivo left ventricular
function.47 We therefore propose that the prediabetic
milieu elicits transcriptional changes (de creased ex -
pression of respiratory chain complex com ponents and
contractile proteins) that contribute to impaired res -
piratory capacity and contractile function observed in
the diabetic heart.
The effects of increased free fatty acids
To further understand how altered circulating fuels may
alter cardiac metabolism and heart function, we also
focused on the effects of elevated free fatty acids usually
found during the prediabetic and the diabetic state. We
determined whether cardiac efficiency, that is the ratio
of cardiac work to myocardial oxygen consumption
(MVO2), is diminished in diabetic hearts. Our data
showed decreased cardiac efficiency in db/db hearts,
namely an 86% increase in myocardial oxygen con sump -
tion (increased mitochondrial respiration and cardiac
fatty acid β-oxidation).43 The extra oxygen cost of
increased fatty acid β-oxidation relative to glucose oxi -
da tion will, however, make a minor contribution since
there is only a theoretical 11% decrease in the efficiency
of hearts shifting from complete glucose oxi dation to
complete fatty acid β-oxidation. We therefore propose
that intracellular futile metabolic cycles and upregu -
lation of mitochondrial uncoupling proteins (in duced by
elevated plasma fatty acids) could dissipate the proton
gradient across the inner mitochondrial mem brane.48
Since an early increase in fatty acid β-oxida tion pre -
cedes the onset of contra ctile dys function such pro -
nounced ‘oxygen wasta ge’ may compromise hea rt
func tion when oxygen demand is  high (e.g . eleva -
ted workloads ) or when oxygen delivery is  limited
(e.g . a n ischemic insult). 
The effects of elevated glucose levels
We are also focusing on the damaging effects of ele -
vated glucose levels (hyperglycemia), a risk factor that
forms part of the metabolic syndrome, on the heart.
There is a growing shift in the paradigm for the role of
dietary macronutrient composition in the inci dences of
CVD, as studies show that there is no reduction in CVD
with a low-fat/high-carbohydrate diet but there is rather
reduced risk with a diet low in sugar and rapidly ab -
sorbed starches and high in polyun saturated fatty
acids.49,50 Moreover, there is increasing evidence from
animal studies showing that a diet with a high glycemic
load, typical of highly processed foods, accelerates the
development and progression of CVD50 (see Figure 4). 
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Our major foc us is on the detrimental effects of in -
creased activation of a glucose-based metabolic path -
way, the hexosamine biosynthetic pathway (HBP). The
HBP usually acts as a ‘fuel sensor’ under normal condi -
tions, in other words, sensing glucose and free fatty acid
availability and repartitioning fuel substrates into
suitable storage depots within the body (reviewed in 
51 and 52). After uptake, glucose is rapidly converted 
to glucose-6-phosphate and thereafter to fructose-6-
phosphate. Fructose-6-phosphate is the entry point for
the HBP, forming glucosamine-6-phosphate. Production
of glucosamine-6-phosphate is catalyzed by glutamine:
fructose-6-phosphate amidotransferase (GFAT), the
rate-limiting enzyme of the HBP (see Figure 5). Through
a series of reactions, glucosamine 6-phosphate is ulti -
mate ly converted to UDP-N-acetylglucosamine (UDP-
GlcNAc), the end product of the HBP. UDP-GlcNAc is
a substrate for O-GlcNAc transferase (OGT) that cata -
lyzes the O-linked transfer of GlcNAc to specific serine/
threonine residues of target proteins. Con verse ly, O-
GlcNAcase (OGA) catalyzes the reverse re ac tion,
name ly the removal of O-GlcNAc residues from target
proteins. O-GlcNAc modification is implicated in a di -
verse range of intracellular reactions and pathways, in -
cluding altering protein degradation and intracellular
loca li zation, modulating protein-protein interactions and
regulating transcriptional mechanisms.51,52
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Figure 4: Flow diagram
depicting the interaction
between a ‘junk food’ diet,
obesity and hypertension 
The diagram depicts an evolving
paradigm characterizing the
effects of diet on left ventricular
remodelling. A diet high in sugar
and saturated fats promotes
myocardial dysfunction through
hyper tension-dependent and
independent pathways (adapted
from 50).
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Figure 5: The hexosamine
biosynthetic pathway (HBP) 
Production of glucosamine-6-
phosphate is catalyzed by
glutamine: fructose-6-phosphate
amidotransferase (GFAT).
Glucosamine 6-phosphate is
ultimately converted to UDP-N-
acetylglucosamine (UDP-
GlcNAc), the HBP’s end
product. O-GlcNAc transferase
(OGT) catalyzes the O-linked
transfer of GlcNAc to target
proteins while O-GlcNAcase
(OGA) catalyzes the reverse
reaction. 
Diet rich in sugars, 
high glycemic starch 
& saturated fat
Hypertension
Obesity
Heart failure
Myocardial pathology
pathophysiologic cardiac hypertrophy
↑ glucose uptake & ↓ mitochondrial function
↑ oxidative damage
↑ hexosamine biosynthetic pathway flux 
↑ cardiomyocyte apoptosis
However, we propose that chronically activated HBP
flux is maladaptive and can contribute to pathophy sio -
logic phenotypes. For example, our laboratory recently
delineated a novel signaling pathway whereby hyper -
glycemia triggers oxidative stress, the HBP and cell
death (apoptosis) in heart cells and in insulin-resistant
rats.53,54 We also found increased O-GlcNAcylation of
an apoptotic peptide, BAD, together with higher BAD-
Bcl-2 dimer formation (pro-apoptotic). We propose
that O-GlcNAcylation maintains BAD in its active form,
in other words, dimerizing with Bcl-2 and resulting in
increased apoptosis (see Figure 6). Previous work
showed that a ‘yin-yang’ relationship may prevail be -
tween phosphorylation and O-GlcNAcylation whereby
they compete for the same site or closely located sites
on target proteins.55 Hence with increased HBP flux, we
found greater O-GlcNAcylation of BAD and reduced
phosphorylation. We propose that O-GlcNAcylation of
BAD occurs in the near vicinity or at the same site(s) as
BAD phosphorylation, resulting in reduced access to
upstream kinases.
We are of the opinion that increased cell death will
lead to impaired cardiac contractile function and
eventually result in ischemic heart disease and/or heart
failure. Our postulate is that poor nutritional choices
(high glycemic diet) activate the HBP leading to in -
creased O-GlcNAcylation of cardiac apoptotic (e.g.
BAD) and insulin signaling proteins, thereby leading to
cell death and impaired insulin signaling, respectively.
This, in turn, will accelerate the development and pro -
gression of insulin resistance and CVD. For example, we
currently hypothesize that hyperglycemia-mediated ele -
va tion of HBP flux increases O-GlcNAcylation of regu -
lators of the insulin signaling pathway (PKB/Akt, AS160),
thereby impairing its function. Here our data show that
increased O-GlcNAcylation of PKB/Akt and AS160 is
associated with decreased GLUT4 trans lo cation to the
sarcolemma (unpublished data). Further more, our
current work also demonstrates that HBP inhibition
signifi cantly blunts the hyperglycemia-induced decrease
in heart function usually observed in response to ische -
mia-reperfusion (unpublished data). 
Together our studies show that high circulating levels
of fuel substrates (glucose and fatty acids) lead to
damaging effects on the heart’s function at baseline and
in response to ischemia-reperfusion. Moreover, these
data have identified several therapeutic targets that may
help alleviate heart diseases that occur in diabetic pa -
tients, for example how to limit free fatty acid-in duced
‘oxygen wastage’ and attenuated mitochondrial ATP
production, or finding ways to decrease HBP acti vation
and its contribution to the onset of insulin re sistance
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Figure 6:  Working model
showing how increased
BAD O-GlcNAcylation
may trigger apoptosis 
Hyperglycemia-induced HBP
flux results in increased 
O-GlcNAcylation of BAD and
decreased BAD phosphory -
lation (inactive state). Thus
increased ‘active’ BAD levels
lead to greater dimerization of 
O-GlcNAcylated BAD and 
Bcl-2. This, in turn, results in
reduced Bcl-2 availability and
less dimerization with Bax.
Free Bax are now able to form
homodimers, leading to
disruption of the mitochondrial
membrane, thereby inducing
apoptosis.
and CVD. In light of this, our work during the last few
years has focused on developing novel therapies to
blunt the effects of chronic HBP activation and its
downstream effects, namely onset of insulin resistance
and cardiac dysfunction.
THE DEVELOPMENT OF 
METABOLIC THERAPIES
The development of novel therapies to treat cardio-metabolic diseases usually takes a considerable
length of time, sometimes decades. This route usually
originates with conception of the original idea, basic ex -
pe rimen tation and further evaluation in smaller and
larger clinical settings. When criteria of safety are satis -
factorily met, drugs are finally approved for treatment
of various illnesses. However, unexpected side-effects
can some times occur after chronic treatment with spe -
ci fic drugs. For example, although antiretroviral treat -
ment dramati cally decreases HIV/AIDS morbidity and
mortality, the long-term effects may include metabolic
derangements and the onset of CVD. This example de -
mon strates the limitation of the reductionist approach
to biomedical science. As a result, additional studies are
required to effectively treat associated cardio-metabolic
diseases associated with chronic antiretroviral treat -
ment. Our laboratory hypothesized that protease inhi -
bitor treat ment elevates oxidative stress that attenuates
contrac tile function at baseline and in response to myo -
cardial ischemia. We are currently investigating this
postu late by establishing a unique rat model of chronic
protease inhibitor utilization (lopinavir/ritonavir treat -
ment for eight weeks). Here our data show that pro -
tease inhi bitor-treated rats exhibited increased body
weights and low-density lipoprotein cholesterol levels.
We also found attenuated contractile function at base -
line follow ing eight weeks of protease inhibitor treat -
ment and increased myocardial cell death (unpublished
data). De creased contractile function per sisted during
the reper fusion period (after an experi mentally induced
ischemic insult). We are currently testing inhibitors of
maladap tive pathways that can eventually be coad minis -
tered with antiretroviral drugs. 
In light of these difficulties, we have focused on
natural agents as a potential therapeutic strategy since
this may result in a more rapid translation into the clinic
and also prove to be more cost-effective, especially
with in the developing world context. Previous work
demonstrated that diabetes results in decreased levels
of thiamine (Vitamin B1), which is essential for normal
functioning of the heart, muscles and nerves.56 Defi -
ciencies in the B-series vitamins are among the key
causative factors leading to diabetic organ damage.57
Hence, thiamine and its lipophilic analogue benfotiamine
can reduce some of the complications associated with
diabetes, for instance cardiomyopathy, retinopathy and
neuropathy.58 Since benfotiamine can decrease HBP
flux, we hypothesized that it is a cardioprotective agent.
Our preliminary data show that benfotiamine treatment
blunts the damaging effects of hyperglycemia and sig -
nificantly improves the heart’s functional recovery in
response to ischemia-reperfusion (unpublished data).
Thus these data demonstrate that benfotiamine is a pro -
mising cardioprotective agent that may ultimately bene -
fit pre- and full-blown diabetic patients suffering from
cardiovascular disease complications.
We also tested whether oleanolic acid (a clove ex -
tract) possesses antioxidant properties. Our in vitro data
demonstrated that oleanolic acid blunted hyper gly -
cemia-induced oxidative stress and apoptosis in heart
cells (unpublished data). It also markedly improved func -
tional recovery of hearts perfused in response to
ischemia-reperfusion under hyperglycemic conditions.
We also performed studies on oxygen lack (hypoxia)
as a cardioprotective strategy. We propose that a mo -
de rate lack of oxygen (physiologic hypoxia) triggers
pro tective signaling pathways, unlike a severe impair -
ment of oxygen supply (pathophysiologic hypoxia) that
may exceed the host organism’s defense apparatus, re -
sul ting in a maladaptive cardiac phenotype (reviewed in
38). Physiologic hypoxia triggers various defense mecha -
nisms, for example erythropoiesis and angioge nesis, to
increase red blood cell mass and oxygen delivery to the
heart. Here we propose that physiologic hypoxia acti -
vates regulatory pathways that mediate long-term
cardiac metabolic remodeling, particularly at the
transcrip tional level. The proposal is that physio logic re -
ac tive oxygen species (ROS) play a central role by
modu lating the activity of redox-sensitive trans cription
factors to induce a fetal gene program (in creased carbo -
hydrate and decreased fatty acid meta bolism) and
increased mitochondrial biogenesis in the heart.38 These
programs will thus increase the efficien cy of energy pro -
duction and augment mitochondrial bio energetic capacity
to sustain cardiac contractile func tion. Collectively
these studies show promise, and the next step would be
to translate some of our findings into the clinic, in other
words, small pilot studies. 
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Normal Pre-diabetic Diabetic
Figure 7: Increased HBP activation parallels fasting glucose levels
Leukocytes stained for O-GlcNAc (Texas red) and cell nuclei (Hoechst blue dye) demonstrate increased red staining 
(O-GlcNAc) for prediabetic and diabetic individuals. 
THE DEVELOPMENT OF
DIAGNOSTIC TOOLS FOR 
CLINICAL APPLICATION
We are also pursuing the development of noveldiagnostic tools to allow for more sensitive and
earlier detection of cardio-metabolic diseases. Although
there are currently tests available to screen for the
onset of diabetes, for example glycosylated hemoglobin
(HbA1c) levels, oral glucose tolerance and fasting blood
glucose levels tests, these methods have limitations. For
example, Saudek et al59 propose that HbA1c is not
always an effective diagnostic tool to identify pre -
diabetes. At the end of their article the authors state,
“There are serious deficiencies in the current criteria
for diagnosing diabetes, including the requirement that
the patient be fasting, and the lack of agreed-on
screening criteria. These deficiencies make it unneces -
sarily inconvenient for clinicians to diagnose diabetes,
thereby delaying the diagnosis and contributing to avoi -
da ble morbidity and mortality.’’ Thus there is a need for
the development of novel diagnostic tools to detect
pre diabetes and diabetes in a timeous, sensitive and
cost-effective manner.
Although rapid protein O-GlcNAcylation occurs
with in white blood cells,60 there is no literature regar -
ding O-GlcNAcylated leukocyte proteins within the pre -
diabetic setting. In light of this, we hypothesized that
there is increased oxidative stress and O-GlcNAcylation
in white blood cells in the prediabetic milieu and that
this may offer a novel diagnostic tool to predict the
onset of insulin resistance. Here our data (flow cyto -
metry and fluorescence microscopy gene ra ted) show
that O-GlcNAcylation of leukocyte proteins changes in
parallel with increasing fasting glucose levels (see Figure
7) (unpublished data). The data show early promise for
the establishment of a sensitive diagnostic test that 
may help improve the detection and manage ment of
type 2 diabetes.
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Figure 8: The impact of external and internal challenges on the heart’s metabolism 
We are of the opinion that markers of the HBP may result in novel diagnostic tools to assess prediabetes, while HBP
inhibition within the prediabetic context may also provide cardioprotection. 
HEART METABOLISM’S 
BALANCING ACT: QUO VADIS?
Treading the tightrope of healthy living in the 21stcentury is an arduous task. The global economy is
characterized by great wealth disparities with serious
health implications. Moreover, the prevailing economic
model struggles to promote equity, efficiency and en -
viron mental sustainability. Also, production for profit
and related consumerism translate into an environ -
mental imbalance in terms of healthy living, for example
pollution, stress, nutritional excess and sedentary life -
styles. Communities are therefore exposed to an in -
creasing number of external stressors that can trigger
internal changes, for example altered myocardial fuel
substrate metabolism.
It therefore becomes a daunting balancing act for the
heart’s metabolism to sustain its energetic production
and output in the midst of prolonged external and
internal challenges. In some instances the heart is able
to successfully adapt, for example increased mitochon -
drial respiratory capacity that sustains the physiologic
hypertrophied heart. However, it is hard to continue its
balancing act(s) in the long-term. Chronically high 
cir culating fuel substrates (e.g. glucose and fatty acids)
trigger maladaptive pathways that result in cell death,
decreased mitochondrial ATP production and the onset
of type 2 diabetes and CVD. Our research work has
iden tified several mechanisms whereby high circulating
fatty acid and glucose levels lead to impaired cardiac
contractility (see Figure 8). Moreover, we have dis -
covered several molecular targets that can be exploited
for diagnostic and therapeutic purposes. If future trans -
lational studies are successful, this should ultimately
improve overall quality of life and well-being and help
diminish the growing global burden of type 2 diabetes
and CVD. However, it is crucial that such efforts go
together with the development of a more integrative
scien tific research approach and a better balanced eco -
nomic framework.
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